Compare SLF & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLF | WAT |
|---|---|---|
| Founded | 1871 | 1958 |
| Country | Canada | United States |
| Employees | 32151 | N/A |
| Industry | Advertising | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3B | 29.2B |
| IPO Year | N/A | 1996 |
| Metric | SLF | WAT |
|---|---|---|
| Price | $63.27 | $293.34 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 17 |
| Target Price | $84.00 | ★ $386.38 |
| AVG Volume (30 Days) | 559.7K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 4.14% | N/A |
| EPS Growth | N/A | ★ 0.47 |
| EPS | N/A | ★ 10.76 |
| Revenue | N/A | ★ $3,165,286,000.00 |
| Revenue This Year | N/A | $104.66 |
| Revenue Next Year | $5.30 | $10.53 |
| P/E Ratio | ★ $14.79 | $26.59 |
| Revenue Growth | N/A | ★ 6.99 |
| 52 Week Low | $52.44 | $275.05 |
| 52 Week High | $69.67 | $414.15 |
| Indicator | SLF | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 44.25 | 32.18 |
| Support Level | $60.96 | $281.33 |
| Resistance Level | $64.01 | $308.14 |
| Average True Range (ATR) | 1.05 | 9.00 |
| MACD | -0.35 | -0.75 |
| Stochastic Oscillator | 25.20 | 21.66 |
Sun Life Financial is one of the Big Three Canadian life insurers. The Canadian business contributed around 38% of adjusted earnings. In that segment, the firm provides health, life insurance, and annuity products to individual and group customers. Its US business is mostly group health and contributed about 20% of the firm's adjusted earnings in 2024. Sun Life also offers life insurance and wealth products in several Asian markets with a strong presence in Hong Kong and the Philippines. The Asia segment contributed around 18% of adjusted 2024 earnings. Its asset management business had around CAD 1.1 trillion total assets under management or administration at the end of 2024 and represents around 34% of the firm's earnings.
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.